Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Voruciclib - Lite Strategy

Next Previous
Drug Profile

Voruciclib - Lite Strategy

Alternative Names: ME-522; P 1446A 05; P-1446; P1446A; Voruciclib

Latest Information Update: 16 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Piramal Life Sciences
  • Developer Lite Strategy; Piramal Enterprises
  • Class Antineoplastics; Benzopyrans; Pyrones; Pyrrolidines; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Cyclin-dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; B-cell lymphoma
  • No development reported Malignant melanoma

Most Recent Events

  • 10 Sep 2025 MEI Pharma is now called Lite Strategy
  • 07 Dec 2024 Updated phrmacodynamics data from the phase I trial in Acute myeloid leukemia, B-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)
  • 07 Dec 2024 Updated efficacy and pharmacokinetics data from the phase I trial in Acute myeloid leukemia, B-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top